We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal

Rhinomed

Rhinomed is a medical technology firm that has developed a patented nasal and respiratory technology platform capable... read more Featured Products: More products

Download Mobile App




World’s Most Child-Friendly Respiratory Swab Addresses Major Challenge of Testing Reluctance

By HospiMedica International staff writers
Posted on 09 Jan 2023
Print article
Image: Rhinoswab Junior is the happy way to swab children for respiratory viruses (Photo courtesy of Rhinomed)
Image: Rhinoswab Junior is the happy way to swab children for respiratory viruses (Photo courtesy of Rhinomed)

One of the pandemics' major challenges has been testing reluctance created by the fear, anxiety and discomfort associated with traditional combined throat and nose swabs. Now, the world’s first nasal swab developed specifically for children features a unique design that addresses this challenge.

Rhinomed Limited (Cremorne, VIC, Australia) has launched the world’s most child-friendly respiratory swab in Europe. Rhinomed has developed the novel Rhinoswab Junior nasal swab designed specifically for children. The Rhinoswab Junior comfortably sits inside the nose and captures a significantly larger yield than standard nasal swabs. Its unique and engaging design removes the fear children experience with existing swabs. It can easily be integrated into existing rapid antigen and PCR tests for a range of respiratory viruses including SARS-CoV-2, RSV, Influenza, etc.

In a clinical trial led by the Murdoch Children’s Research Institute, leading pediatricians compared the current combined nose and throat swabs and saliva collection methods to Rhinoswab Junior. The trial demonstrated that Rhinoswab Junior is the best method for collecting samples from children when considering comfort, consistency, accuracy and efficacy. A National Child Health Poll identified that 74% of parents were reluctant to bring their children in for COVID-19 testing because of the potential trauma and pain of sampling, with up to 30% unlikely to test their children at all. The results of this new trial confirm that Rhinoswab Junior provides a child friendly, more comfortable alternative that addresses these concerns. 88% of children preferred Rhinoswab Junior compared to the standard swab, and it was the preferred method of sample collection for their next test. Rhinoswab Junior’s unique design also means children can collect their own samples, and parents and carers are more likely to ensure children are tested.

These results build on a previous Murdoch Children’s study of 249 hospital samples that concluded that the Rhinoswab Junior is clinically equivalent to a standard combined nose and throat swab, yet preferred by eight out of 10 children and preferred by parents and nursing staff. The trial provided clear compelling evidence of clinical efficacy. Rhinoswab Junior demonstrated significantly more sensitivity than saliva and was able to detect more cases of SARS-CoV-2. The Rhinoswab Junior detected 45 cases when compared to the combined throat and nasal swab which detected 44 SARS-CoV-2 cases, while saliva samples detected just 39 cases. For the first time, clinicians can improve testing uptake and rely on an anterior nares swab without any statistically significant loss in sensitivity.

In the trial, samples were self-collected by 53 children aged 4-18 years, with results demonstrating that Rhinoswab Junior is readily used by children to self-collect, more comfortable and preferred to standard combined nose and throat swabs, highly sensitive and accurate for SARS-CoV-2 detection, and more sensitive and has better COVID-19 case detection than saliva sampling. The trial confirms Rhinoswab Junior is the preferred method of sample collection for respiratory diseases for children whether for PCR or Rapid Antigen testing. Rhinoswab Junior has the potential to improve testing rates for a range of respiratory viruses at home, in schools and in a variety of health settings. Its unique design delivers a standardized sampling methodology for the first time. Rhinoswab Junior is listed for sale as a Class 1 device in Europe (CE Mark), in the USA (FDA), in the UK (MHRA), and in Australia (TGA).

“Reducing the barriers to getting more people tested is crucial. Children remain a critical at risk population and we believe that the Rhinsowab Junior can radically improve testing uptake,” said Rhinomed CEO Michael Johnson. “Rhinomed is proud to have developed a swab that not only works better but removes anxiety and distress – not just for kids, but for their parents and health care workers. Even adults prefer Rhinoswab.”

Related Links:
Rhinomed Limited

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Transport Ventilator
TV80

Print article

Channels

Critical Care

view channel
Image: Peerbridge Cor is a 3-lead, 2-channel wireless AECG that simplifies the testing and diagnostic process (Photo courtesy of Peerbridge Health)

First-of-its-Kind Trial to Measure Ejection Fraction Severity Directly from AI-Enabled Remote ECG Wearable

Echocardiograms are a standard diagnostic tool to measure ejection fraction but require a clinical setting for administration. This can pose challenges such as scheduling delays, staffing shortages, accessibility... Read more

Surgical Techniques

view channel
Image: Fixation screws for ligament to bone repair (Photo courtesy of 4D Medicine)

Novel Biomaterial Platform Opens Up New Possibilities for Implants and Devices

Resorbable biomaterials, crucial for implantable medical devices, have seen little innovation over decades. Materials like Polylactic Acid (PLA), Polycaprolactone (PCL), and Poly Lactic-co-Glycolic Acid... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Business

view channel
Image: The Innovalve transseptal delivery system is designed to enable safe deployment of the Innovalve implant (Photo courtesy of Innovalve Bio)

Edwards Lifesciences Acquires Sheba Medical’s Innovalve Bio Medical

Edwards Lifesciences (Irvine, CA, USA), a leading company in medical innovations for structural heart disease and critical care, has acquired Innovalve Bio Medical LTD. (Ramat Gan, Israel), an early-stage... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.